九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02566 九源基因

休市中 09-25 09:00:00

5.695

+0.000

0.00%

最高5.695	最低5.695	成交量0.00
今开5.695	昨收5.695	日振幅0.00%
总市值13.67亿	流通市值13.67亿	总股本2.40亿
成交额0.00	换手率0.00%	流通股本2.40亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02566","market":"HK","secType":"STK","nameCN":"九源基因","latestPrice":5.695,"timestamp":1790298000098,"preClose":5.695,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":240000000,"shares":240000000,"eps":0.6577298988038746,"marketStatus":"休市中","change":0,"latestTime":"09-25 09:00:00","open":5.695,"high":5.695,"low":5.695,"amount":0,"amplitude":0,"askPrice":5.71,"askSize":200,"bidPrice":5.4,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.6677391464057414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":7,"adr":0,"listingDate":1732723200000,"exchange":"SEHK","adjPreClose":5.695,"dividendRate":0.011648,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02566","defaultTab":"news","newsList":[{"id":"1135929778","title":"九源基因9月24日回购10.18万股股份，耗资约56.81万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135929778","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135929778?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:30","pubTimestamp":1790253058,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年9月24日公告翌日披露报表，宣布当日在香港联交所场内以每股5.50港元至5.70港元的价格回购H股普通股101,800股，合计耗资约568,063港元，占2026年9月17日公司已发行股本约0.04245%。九源基因此前于2026年6月15日通过回购授权，可回购股份总数24,151,640股。九源基因在公告中确认，本次回购严格遵循香港联交所上市规则及相关法律法规要求，并将继续履行信息披露义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"九源基因9月24日回购10.18万股股份，耗资约56.81万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669498814","title":"九源基因(02566)9月24日斥资56.81万港元回购10.18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498814","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669498814?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:27","pubTimestamp":1790252857,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，于2026年9月24日，该公司斥资56.81万港元回购10.18万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170622049","title":"九源基因（02566）2026年中期营收6.31亿元，经调整净利润0.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170622049","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170622049?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:42","pubTimestamp":1790152920,"startTime":"0","endTime":"0","summary":"九源基因发布2026年中期财报，报告期内，公司实现营收6.31亿元，同比下降1.2%；经调整净利润0.91亿元，同比增长1.2%。毛利率为81.1%，较上年同期的82.2%略有下降。经营活动所得现金流达到1.07亿元，较上年同期的0.13亿元有显著提升。公司保持了稳健的盈利能力，同时研发投入较上年同期有所增加，研发费用达0.69亿元。销售及市场开支为3.15亿元，较上年同期下降约8.9%，反映出公司成本管控趋于优化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"九源基因（02566）2026年中期营收6.31亿元，经调整净利润0.91亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162690383","title":"九源基因（02566）2026年首场临时股东大会通过两项议案 投票赞成率均达100%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162690383","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162690383?lang=zh_cn&edition=full","pubTime":"2026-09-18 21:45","pubTimestamp":1789739133,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司9月18日公告披露，公司于2026年9月18日召开2026年第一次临时股东大会，各项议案均以全票通过。本次临时股东大会以现场方式在浙江省杭州市举行，由董事会主席傅航主持。会议召集和召开程序符合中国法律法规、香港联合交易所有限公司证券上市规则及公司章程的相关规定。现场及授权代表合计1名股东出席会议，持有110,601,750股股份，占有表决权股份总数的约46.12%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101883867","title":"九源基因回购23.68万股股份，涉资约131.64万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101883867","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101883867?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:21","pubTimestamp":1789644068,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年9月17日在香港联交所披露翌日披露报表，宣布当日于联交所场内执行了H股回购操作。公告显示，此次公司共回购236,800股H股，占回购前公司已发行股本的0.09856%，每股回购价格在港币5.499至5.600港元之间，合计支付约131.64万港元。公司确认，本次回购已获董事会授权并严格遵守香港联交所主板上市规则和相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九源基因回购23.68万股股份，涉资约131.64万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135444871","title":"九源基因（02566）9月16日回购20.52万股股份，总额约112.86万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135444871","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135444871?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:56","pubTimestamp":1789559787,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年9月16日发布翌日报表公告，披露公司在香港联交所场内回购股份的最新进展。根据公告，九源基因当日回购20.52万股股份，占该公司回购前已发行股份总数约0.08541%。本次回购的每股价格介于港币5.465元至港币5.50元之间，合计付款金额约为港币112.86万元。本次回购根据公司于2026年6月15日通过的购回授权进行，授权可回购的股份总数为24,151,640股。本公告由九源基因联席公司秘书黄秀签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"九源基因（02566）9月16日回购20.52万股股份，总额约112.86万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988680","title":"九源基因(02566.HK)9月16日斥资112.86万港元回购20.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988680","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667988680?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:51","pubTimestamp":1789559516,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157969641","title":"九源基因9月15日回购3,600股，涉资19,359港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157969641","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157969641?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:50","pubTimestamp":1789473055,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年9月15日发布公告，披露最新股份购回事宜。公告显示，九源基因于9月15日通过香港联交所场内回购H股3,600股，占该公司已发行股本约0.0015%，回购价格区间介乎每股5.20港元至5.40港元，合计支付金额19,359港元。回购完成后，九源基因已发行股份变动为240,266,400股，库存股份增至5,132,400股，公司总股本仍为245,398,800股。根据公告，该次回购已取得公司于2026年6月15日通过的回购授权，最高允许回购24,151,640股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"九源基因9月15日回购3,600股，涉资19,359港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667446506","title":"九源基因(02566.HK)9月15日斥资1.94万港元回购3600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667446506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667446506?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:47","pubTimestamp":1789472833,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188494302","title":"九源基因9月11日回购2万股，耗资约10.60万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188494302","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188494302?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:32","pubTimestamp":1789126351,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年9月11日披露翌日披露报表，宣布当日在香港联交所场内回购普通股H股2万股，占回购前现有已发行股份约0.00832%。本次回购最高价为每股5.395港元，最低价为每股5.23港元，合计耗资约10.60万港元。回购完成后，公司已发行股份总数仍为245,398,800股，其中已发行且不包括库藏股的股份数量降至240,270,000股，库存股增至5,128,800股。九源基因方面确认，本次回购符合香港联交所证券上市规则及相关法律法规，已履行必要的审批程序。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九源基因9月11日回购2万股，耗资约10.60万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529970","title":"九源基因(02566.HK)9月11日斥资10.6万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529970","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666529970?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:13","pubTimestamp":1789125185,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107466247","title":"九源基因8月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1107466247","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107466247?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:05","pubTimestamp":1788516341,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年9月4日发布2026年8月股份变动月报表。报告期内，九源基因未进行新增股份发行、股份回购、注销或库存股变动，公司股本结构保持稳定。公告称，截至2026年8月末，九源基因已发行股份在外数量240,290,000股，满足香港联交所相关上市规则对于公众持股比例的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193919165","title":"九源基因（02566）拟于9月18日召开临时股东大会 审议募资用途变更及章程修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1193919165","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193919165?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:13","pubTimestamp":1788167611,"startTime":"0","endTime":"0","summary":"九源基因公告，将于2026年9月18日（星期五）14:30在杭州市钱塘区白杨街道8号大街23号第三会议室召开临时股东大会，股权登记日为同日；H股过户登记将于9月15日至18日暂停。所有股东可亲自或委任代表出席并行使表决权。H股持有人须于9月14日16:30前完成过户手续。会议预计用时不超过半天，交通及食宿费用自理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150090541","title":"九源基因（02566）拟动用最高1亿元延续H股回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1150090541","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150090541?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:45","pubTimestamp":1787139957,"startTime":"0","endTime":"0","summary":"8月19日，九源基因公告称，董事会已决议在现有回购授权有效期内，继续实施H股回购计划，拟使用自有资金回购H股，金额上限为人民币1亿元。根据公告内容，股东于2026年6月15日股东周年大会上已向董事会授出回购授权，可回购数量不超过截至该日已发行H股总数10.0%。公司指出，每次回购的H股价格不得高于回购前连续五个交易日H股平均收市价的5.0%。公司提醒投资者在买卖股份时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162898705","title":"九源基因（02566）续签多项框架协议　2027—2029年关联交易年度上限披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1162898705","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162898705?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:45","pubTimestamp":1787139925,"startTime":"0","endTime":"0","summary":"8月19日，九源基因公告，董事会已批准与华东医药及中美华东续签五项持续关连交易相关协议及安排，涉及采购、分销、生产服务及收益分成等，详情如下：。拟定年度上限均为5.1百万元。2027年年度上限为40.0百万元。拟定年度上限分别为2027年10.0百万元、2028年12.0百万元及2029年8.0百万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498440","title":"九源基因(02566.HK)拟回购金额最多为1亿元的H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498440","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660498440?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:44","pubTimestamp":1787139845,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182187651","title":"九源基因（02566）发布2026年中期业绩：上半年营收6.31亿元 净利同比增长1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182187651","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182187651?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:41","pubTimestamp":1787139686,"startTime":"0","endTime":"0","summary":"2026年8月19日，九源基因公布截至2026年6月30日止六个月未经审核运营数据。期内公司实现收入6.31亿元，同比下降1.2%；归属于母公司股东的净利润为9,126.9万元，同比增长1.2%。公司于2026年5月15日完成1.3630亿股未上市股份转换为H股的全流通。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193612325","title":"杭州九源基因生物制药股份有限公司：批准最高1亿元人民币H股回购计划至授权期满","url":"https://stock-news.laohu8.com/highlight/detail?id=1193612325","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193612325?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:41","pubTimestamp":1787139669,"startTime":"0","endTime":"0","summary":"杭州九源基因生物制药股份有限公司正式通过一项H股回购方案，规模上限设定为1亿元人民币，该计划将持续有效至相关授权期限届满之日。此举标志着公司在资本运作层面迈出重要一步，旨在优化股本结构并提升股东价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440154","title":"九源基因(02566)公布中期业绩 母公司股东应占净利润9126.9万元 同比增长1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440154","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440154?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:39","pubTimestamp":1787139599,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 公布2026年中期业绩，收入约6.31亿元，同比减少1.23%;母公司股东应占净利润9126.9万元，同比增长1.21%;每股盈利0.38元。报告期内，凭借公司优质的产品供应能力及成本优势，公司两款已集采产品吉欧停、亿喏佳顺利完成续约;此外，去年已上市产品吉新芬、吉立欣在报告期内销售数量均保持较快的增速。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141202611","title":"九源基因（02566）将于8月19日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1141202611","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141202611?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:56","pubTimestamp":1786362969,"startTime":"0","endTime":"0","summary":"九源基因（02566）8月10日在港交所公告，董事会会议定于2026年8月19日（星期三）举行，拟审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其刊发事宜，同时审议中期股息建议（如有）。\n公告显示，董事会目前由执行董事傅航先生、周伟先生，职工代表董事徐飞虎先生，非执行董事吴诗航先生、Albert Esteve Cruella先生、费俊杰先生、严瑋婷女士，以及独立非执行董事周智慧先生、何美仪女士、周德敏博士、黄文礼博士组成。\n此次董事会的召开，将为市场提供公司2026年上半年经营表现及分红计划（如有）的最新信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.china-gene.com","stockEarnings":[{"period":"1week","weight":0.0517},{"period":"1month","weight":0.0848},{"period":"3month","weight":-0.0164},{"period":"6month","weight":-0.2745},{"period":"1year","weight":-0.4825},{"period":"ytd","weight":-0.2381}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州九源基因生物医药股份有限公司（原名：杭州九源基因工程股份有限公司）是一家主要从事研发、生产及商业化生物药品和医疗器械的中国公司。该公司专注于骨科、代谢疾病、肿瘤及血液治疗领域。该公司的骨科产品包括骨优导骨修复材料。该公司的肿瘤产品包括吉利芬、吉巨芬、吉欧停、吉芙惟、吉坦苏。该公司的血液产品包括吉派林、亿喏佳。该公司的产品主要用于治疗糖尿病、多发性骨髓瘤、血小板减少症、中性粒细胞减少症等疾病。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"九源基因","nameEN":"JIUYUAN GENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九源基因(02566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九源基因,02566,九源基因股票,九源基因股票老虎,九源基因股票老虎国际,九源基因行情,九源基因股票行情,九源基因股价,九源基因股市,九源基因股票价格,九源基因股票交易,九源基因股票购买,九源基因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九源基因(02566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}